<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920128-0040</DOCNO><DOCID>920128-0040.</DOCID><HL>   Business Brief -- Schering-Plough Corp.:   Concern Posts 14% Increase   In Fourth-Quarter Earnings</HL><DATE>01/28/92</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   SGP</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)EARNINGS (ERN)</IN><NS>EARNINGS (ERN)</NS><RE>NEW JERSEY (NJ)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Schering-Plough Corp., Madison, N.J., reported fourthquarter and 1991 net income both rose 14%, on strong gains inthe international pharmaceutical businesses andover-the-counter drug sales.   For the quarter, earnings rose to $149 million, or 71cents a share, compared with the prior year's $130.6 million,or 58 cents a share. Sales rose 8% to $865.6 million, from$800 million. Excluding the effect of foreign currencytranslations, sales would have risen 11%, the company said.</LP><TEXT>   For 1991, net income rose to $645.6 million, or $3.01 ashare, compared with 1990's $565.1 million, or $2.50 a share.Sales rose 9% to $3.62 billion from the prior year's $3.32billion. Foreign currency exchange had minimal effect onfull-year sales, and excluding 1990 sales from the Maybellinecosmetics unit, which the company divested itself of in July1990, sales for 1991 would have been 13% higher than theprevious year's.   The pharmaceutical company attributed the year's resultsto strong international sales, which grew 12% in 1991. U.S.pharmaceutical sales rose 10%.</TEXT></DOC>